Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.
Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.
复制标题
DOI：
10.1016/j.addr.2015.04.019
复制
发表时间：
2016-01-15
影响因子：
16.1
通讯作者：
Radisic M
中科院分区：
文献类型：
--
作者：
Feric NT;Radisic M
工程化的功能性人体心脏组织模仿天然成人的形态和功能表型一直是人们一直以来的目标。在过去的5年里，由于人类干细胞生物学的最新进展，心脏组织工程领域已经从各种动物来源的心脏组织过渡到生产第一代人类工程心脏组织(HECTs)。尽管取得了这一进展，但与天然成人心肌相比，迄今为止产生的hECT仍然不成熟。在这篇综述中，我们主要从再生医学、药物发现、临床前安全性测试和病理生理学研究等方面对hECTs的成熟性挑战、技术现状和未来前景作一综述。
Engineering functional human cardiac tissue that mimics the native adult morphological and functional phenotype has been a long held objective. In the last 5 years, the field of cardiac tissue engineering has transitioned from cardiac tissues derived from various animal species to the production of the first generation of human engineered cardiac tissues (hECTs), due to recent advances in human stem cell biology. Despite this progress, the hECTs generated to date remain immature relative to the native adult myocardium. In this review, we focus on the maturation challenge in the context of hECTs, the present state of the art, and future perspectives in terms of regenerative medicine, drug discovery, preclinical safety testing and pathophysiological studies.